Clairity Raises $43 Million Series B to Expand FDA-Authorized AI Breast Cancer Risk Platform
Clairity, an AI-driven precision health company developing advanced predictive medical imaging tools, has secured substantial venture funding to accelerate commercialization of its FDA-authorized breast cancer risk prediction platform and expand its broader predictive health pipeline. In November 2025, the company announced it had raised $43 million in Series B financing to support the rollout and expansion of its flagship product, Clairity Breast, as well as development of additional offerings such as Clairity Breast 3D and Clairity Heart focused on cardiovascular risk prediction.
The $43 million Series B round was led by ACE Global Equity and Santé Ventures, with continued support from mission-oriented backers such as the Breast Cancer Research Foundation and several new investors joining the syndicate. This mix of strategic healthcare and venture investors reflects confidence in Clairity’s approach to transforming routine medical imaging into a tool for early risk assessment and preventive care.
Clairity was founded in 2020 with a mission to shift the standard of care in cancer and chronic disease from reactive diagnosis to proactive prevention by leveraging artificial intelligence and deep learning to extract meaningful predictive insights from standard medical images. Its flagship product, Clairity Breast, became the first FDA-authorized AI platform capable of estimating a woman’s five-year risk of developing breast cancer directly from a routine mammogram, offering clinicians and patients a proactive risk assessment that could enable earlier intervention and more personalized care.
With the Series B funding secured, Clairity plans to accelerate commercialization efforts in the United States, expand partnerships with leading imaging centers and health systems, and support broader adoption of its AI platform across community imaging facilities. A key goal for the company is to make predictive imaging accessible to a wider population, enabling clinicians to identify patients at elevated risk before cancer develops and tailor care plans accordingly.
In addition to driving U.S. commercialization, the capital will be deployed to enhance Clairity’s development pipeline, including advancing Clairity Breast 3D and Clairity Heart — predictive tools that apply the company’s deep learning framework to 3D mammography and cardiovascular risk prediction, respectively. This expansion into additional disease areas underscores Clairity’s ambition to leverage routine diagnostic imaging for a variety of predictive health use cases, unlocking greater value from standard exams.
President and CEO Jeff Luber described the Series B financing as a milestone in Clairity’s evolution, enabling the firm to transition from regulatory achievement and initial health system deployment toward broader market adoption and long-term growth. Following FDA authorization of Clairity Breast and initial commercial rollouts at major health systems, the company is preparing for a national expansion that includes pursuing reimbursement pathways — a critical step in ensuring sustainable integration of AI-based risk prediction into standard clinical practice.
Founder Connie Lehman, MD, PhD, emphasized that Clairity’s technology represents a paradigm shift in breast imaging by using existing mammographic data to predict future cancer risk, rather than merely detecting disease after it is visible. By empowering clinicians and patients with predictive insights, the platform aims to reduce the incidence of late-stage diagnoses and transform care from detection to prevention.
Investor enthusiasm for the company’s vision was reflected in comments from partners across the financing syndicate. Executives from both ACE Global Equity and Santé Ventures highlighted Clairity’s combination of scientific rigor, regulatory validation, and potential for broad clinical impact. The Breast Cancer Research Foundation echoed its ongoing commitment to prevention, noting that Clairity’s predictive platform aligns with its mission to reduce the global burden of breast cancer.
Clairity’s $43 million Series B brings its total known institutional funding to a significant level as it transitions into a commercial phase at a time when AI adoption in radiology and preventive medicine is expanding rapidly. The funding underscores investor confidence in the company’s technology, leadership, and strategy to harness medical imaging data for early risk assessment and disease prevention — an emerging frontier in healthcare innovation.
As Clairity scales its commercial operations and broadens its product portfolio, it aims to help reshape preventive healthcare by delivering actionable insights that empower clinicians and patients to make informed decisions long before disease manifests clinically.
